Search results for "ASES"

showing 10 items of 26804 documents

Reply to Comment on: 'Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine'

2017

Reply to Comment on: ‘Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine’

0301 basic medicineLaser Microscopymedicine.medical_specialtygenetic structuresConfocalAdministration TopicaleducationDry Eye SyndromesOphthalmic SolutionCornea03 medical and health sciencesImmunosuppressive Agent0302 clinical medicineOphthalmologyCorneaMicroscopyCorrespondenceMedicineHumansIn patientOphthalmology; Sensory Systems; Dry Eye; Corneal confocal scanning laser microscopyCorneal confocal scanning laser microscopyMicroscopy Confocalbusiness.industryDry Eyeeye diseasesSensory SystemsOphthalmology030104 developmental biologyOphthalmic solutionsmedicine.anatomical_structure030221 ophthalmology & optometryCyclosporineDry Eye Syndromessense organsOphthalmic SolutionsbusinessImmunosuppressive AgentsHuman
researchProduct

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

2018

Background & aims AASLD/IDSA treatment guidelines for hepatitis C virus (HCV) infection state that testing for quantitative HCV RNA can be considered at the end of antiviral treatment (EOT) with interferon-free regimens. However, it remains unclear how to respond to a detectable or even quantifiable HCV RNA result. The aim of this study was to analyse the frequency and predictive value of detectable and quantifiable HCV RNA results at the EOT in patients with HCV genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort. Methods A retrospective analysis of the DHC-R (Deutsches Hepatitis C-Register, German Hepatitis C-Registry) coh…

0301 basic medicineLedipasvirMalemedicine.medical_specialtySofosbuvirSustained Virologic ResponseHepatitis C virusMedizinHepacivirusmedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineGermanyRibavirinMedicineHumansClinical significanceRegistriesRetrospective StudiesHepatitisFluorenesHepatologybusiness.industryRibavirinvirus diseasesHepatitis CViral Loadmedicine.diseaseHepatitis Cdigestive system diseases030104 developmental biologychemistryRNA Viral030211 gastroenterology & hepatologyBenzimidazolesFemaleSofosbuvirbusinessUridine MonophosphateViral loadmedicine.drug
researchProduct

Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran

2018

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) and responsive patients in a major focus in southeastern Iran. A case-control study was conducted from April 2015 to October 2016 in the southeast of Iran. Patients were recruited in a major ACL focus from unresponsive and responsive cases. These patients were compared for environmental, clinical, and…

0301 basic medicineLeishmania tropicamedicine.medical_treatmentSocial Scienceslcsh:MedicineScarsCryotherapyIranPathology and Laboratory MedicineLogistic regressionPolymerase Chain ReactionGeographical Locations0302 clinical medicineRisk FactorsZoonosesMedicine and Health Scienceslcsh:ScienceLeishmaniasisProtozoansLeishmaniaMultidisciplinaryGeographybiologyEukaryotaInfectious Diseasesmedicine.symptomResearch ArticleNeglected Tropical Diseasesmedicine.medical_specialtyAsiaPatients030106 microbiology030231 tropical medicineLeishmaniasis CutaneousHuman GeographyLesion03 medical and health sciencesSigns and SymptomsCutaneous leishmaniasisDiagnostic MedicineInternal medicineParasitic DiseasesmedicineHumansProtozoan Infectionsbusiness.industrylcsh:ROrganismsHealth Risk AnalysisBiology and Life SciencesOdds ratioDNA ProtozoanTropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansConfidence intervalHealth CareAge GroupsLeishmania tropicaCase-Control StudiesPeople and PlacesLesionsEarth SciencesHousingPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Entrapment of Citrus limon var. pompia Essential Oil or Pure Citral in Liposomes Tailored as Mouthwash for the Treatment of Oral Cavity Diseases

2020

This work aimed at developing a mouthwash based on liposomes loading Citrus limon var. pompia essential oil or citral to treat oropharyngeal diseases. Vesicles were prepared by dispersing phosphatidylcholine and pompia essential oil or citral at increasing amounts (12, 25 and 50 mg/mL) in water. Transparent vesicle dispersions were obtained by direct sonication avoiding the use of organic solvents. Cryogenic transmission electron microscopy (cryo-TEM) confirmed the formation of unilamellar, spherical and regularly shaped vesicles. Essential oil and citral loaded liposomes were small in size (~110 and ~100 nm, respectively) and negatively charged. Liposomes, especially those loading citral, …

0301 basic medicineLemonsSonicationkeratinocyte migrationlcsh:Medicinelcsh:RS1-441Pharmaceutical Sciencehydrogen peroxide02 engineering and technologyMalalties de la bocaCitral<i>Streptococcus mutans</i>law.inventionlcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compoundlawPhosphatidylcholinescratch assayDrug DiscoveryLlimonesanticaries activityKeratinocyte migration<i>Citrus limon</i> essential oilHydrogen peroxideEssential oilLiposomeOlis essencialsChromatographyVesiclelcsh:RStreptococcusEstreptococs021001 nanoscience & nanotechnology030104 developmental biologyMouth diseaseschemistryEssences and essential oilsMolecular Medicine0210 nano-technology
researchProduct

Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity

2016

Background The association between leptin and complement in hepatitis C virus (HCV) infection remains unknown. Methods A prospective study was conducted including 474 (250 genotype 1, 224 genotype 2) consecutive chronic hepatitis C (CHC) patients who had completed an anti-HCV therapy course and undergone pre-therapy and 24-week post-therapy assessments of interferon λ3-rs12979860 and HCV RNA/genotypes, anthropometric measurements, metabolic and liver profiles, and complement component 3 (C3), C4, and leptin levels. Results Of the 474 patients, 395 had a sustained virological response (SVR). Pre-therapy leptin levels did not differ between patients with and without an SVR. Univariate and mul…

0301 basic medicineLeptinRNA virusesMaleSteatosisSustained Virologic ResponsePhysiologyPeptide Hormoneslcsh:MedicineAminotransferasesHepacivirusmedicine.disease_causeGastroenterologyBiochemistryBody Mass IndexCytopathologychemistry.chemical_compoundMathematical and Statistical TechniquesHomeostasisProspective Studieslcsh:SciencePathology and laboratory medicineMultidisciplinaryComplement component 3Hepatitis C virusLeptinAlanine TransaminaseComplement C4Hepatitis CComplement C3Medical microbiologyMiddle AgedLipidsEnzymesmedicine.anatomical_structureCholesterolVirusesPhysical SciencesRNA ViralFemaleViral ClearancePathogensStatistics (Mathematics)Research ArticleAdultmedicine.medical_specialtyGenotypeHepatitis C virusResearch and Analysis MethodsMicrobiologyAntiviral AgentsPolymorphism Single Nucleotide03 medical and health sciencesTransferasesWhite blood cellInternal medicineVirologymedicineHumansStatistical MethodsAgedMedicine and health sciencesFlavivirusesCholesterolbusiness.industryInterleukinslcsh:ROrganismsViral pathogensBiology and Life SciencesProteinsComplement System ProteinsHepatitis C Chronicmedicine.diseaseHormonesHepatitis virusesMicrobial pathogens030104 developmental biologychemistryAnatomical PathologyImmunologyMultivariate AnalysisEnzymologylcsh:QInterferonsSteatosisbusinessPhysiological ProcessesBody mass indexMathematicsViral Transmission and InfectionPLoS ONE
researchProduct

Communication about vaccination: A shared responsibility

2016

ABSTRACT Vaccine hesitancy is an important issue to be addressed, due to the risk of decrease of vaccination coverage and consequent control of preventable diseases. While it is not considered a specific determinant, poor or inadequate communication can contribute to vaccine hesitancy and negatively influence vaccination uptake. As a contribution to the ongoing discussion regarding this theme and in the perspective of the implementation of the upcoming national vaccination plan in Italy, the Erice Declaration was drafted by experts in the field of immunization following a 5-day residential, independent workshop regarding communication topics in vaccinology. The aim of the current letter is …

0301 basic medicineLetter030106 microbiologyImmunologyControl (management)educationDeclarationCommunicable DiseasesEducation03 medical and health sciences0302 clinical medicineDisease TransmissionDisease Transmission InfectiousImmunology and AllergyMedicineHumans030212 general & internal medicineHealth EducationPharmacologyvaccination coveragebusiness.industrycommunicationHealth PolicyVaccinationInfectiousnational vaccination planPublic relationsPatient Acceptance of Health CareVaccinationIdentification (information)Immunizationcommunication; Italy; national vaccination plan; vaccination coverage; vaccine hesitancy; Communicable Diseases; Disease Transmission Infectious; Education; Health Policy; Humans; Italy; Vaccination; Health Communication; Health Education; Patient Acceptance of Health CareItalyHealth CommunicationVaccination coverageImmunologyItaly; communication; national vaccination plan; vaccination coverage; vaccine hesitancyvaccine hesitancybusinessShared responsibility
researchProduct

Apnea events in neonatal age: A case report and literature review.

2019

Abstract Background Among the most common autonomic signs visible in preterm neonates, apnea can represent the first sign of several neurologic and non-neurologic disorders, and seizure is a relatively infrequent cause. Herein authors present a case of neonatal autonomic apnea, discussing the polygraphic video-EEG features of this pathological entity and the differential diagnosis with central apnea and autonomic apnea. Case report A female preterm Caucasian infant (29 + 4 weeks' gestational age (GA)), first twin of a twin pregnancy, at birth was intubated and surfactant administration was performed. She was ventilated via invasive ventilation for three days, with subsequent weaning with no…

0301 basic medicineLevetiracetamCentral apneaVideo RecordingDiseasesInfant Premature Diseases0302 clinical medicinenewbornDiagnosisHypoxiaApneaSleep apneaGestational ageElectroencephalographyGeneral MedicineSleep Apnea CentralAnesthesiaNervous System Diseases; Bradycardia; Cyanosis; Diagnosis Differential; Humans; Hypoxia; Infant Newborn; Infant Premature; Infant Premature Diseases; ; Sleep ApneaBreathingAnticonvulsantsFemalemedicine.symptomInfant PrematureBradycardiaSleep ApneaContext (language use)Gestational AgeNODiagnosis Differential03 medical and health sciencesSeizuresHeart ratemedicineBradycardiaDiseases in TwinsHumansPrematureCyanosisbusiness.industryInfant NewbornInfantapneamedicine.disease030104 developmental biologyAutonomic Nervous System DiseasesDifferentialNervous System Diseasesbusinesspreterm030217 neurology & neurosurgeryneurologic disorders
researchProduct

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease.

2018

L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used. Deep brain stimulation (DBS) is a safe and highly effective treatment option in patients with PD. Even though a clear understanding of the mechanisms of both treatment methods is yet to be obtained, the combination of both treatments is the most effective standard evidenced-based therapy to date. Recent studies have demonstrated that DBS is a therapy option even in the early course of the disease, when first complications arise despite a rigorous adjustment of the pharmacological treatment. The unique feature of this therapeu…

0301 basic medicineLevodopaParkinson's diseaseDeep brain stimulationglobus pallidus internus (GPi)medicine.medical_treatmentParkinson's diseaseCentral nervous systemStimulationDiseaseReviewlcsh:RC346-42903 medical and health sciencesTherapeutic approach0302 clinical medicinemedicinelevodopadeep brain stimulation (DBS)lcsh:Neurology. Diseases of the nervous systembusiness.industryDopaminergicmedicine.diseasenervous system diseases030104 developmental biologymedicine.anatomical_structureNeurologyNeurology (clinical)businessNeurosciencesubthalamic nucleus (STN)030217 neurology & neurosurgerymedicine.drugFrontiers in neurology
researchProduct

Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson’s Disease?

2020

Deep brain stimulation (DBS) is an established therapy for the management of Parkinson's disease (PD). However, DBS is indicated as the disease progresses and motor complications derived from pharmacological therapy arise. Here, we evaluate the potential of DBS prior to levodopa (L-Dopa) in improving quality of life (QoL), challenging the state of the art for DBS therapy. We present data on clinical manifestation, decision finding during early indication to DBS, and trajectories after DBS. We further discuss current paradigms for DBS and hypothesize on possible mechanisms. Six patients, between 50 and 67 years old, presenting at least 5 years of PD symptoms, and without L-Dopa therapy initi…

0301 basic medicineLevodopamedicine.medical_specialtyDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDiseaselcsh:RC321-57103 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifemedicineAdverse effectlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchsubthalamic nucleusbusiness.industryGeneral Neuroscienceearly deep brain stimulationmedicine.diseasenervous system diseasesdeep brain stimulationClinical trialSubthalamic nucleusearly intervention030104 developmental biologysurgical procedures operativenervous systemParkinson’s diseasebusinesstherapeutics030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Neuroscience
researchProduct

Neurodegeneration in tauopathies and synucleinopathies.

2016

International audience; While increasing life expectancy is a major achievement, the global aging of societies raises a number of medical issues, such as the development of age-related disorders, including neurodegenerative diseases. The three main disease groups constituting the majority of neurodegenerative diseases are tauopathies, alpha-synucleinopathies and diseases due to repetitions of glutamine (including Huntington's disease). In each neurodegenerative disease, the accumulation of one or more aggregated proteins has been identified as the molecular signature of the disease (as seen, for example, in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lat…

0301 basic medicineLewy Body DiseaseParkinson's disease[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyParkinson's diseaseDementia with Lewy bodiesMédecine humaine et pathologieDiseaseBioinformatics03 medical and health scienceschemistry.chemical_compound0302 clinical medicineParkinsonian Disorders[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineDementiaHumansCytoskeletonSynucleinopathiesAlpha-synucleinInclusion Bodiesbusiness.industryDementia with Lewy bodiesNeurodegenerative diseasesNeurodegenerationassociationBrainNeurodegenerative DiseasesAlzheimer's diseasemedicine.disease3. Good health030104 developmental biologyNeurologychemistryTauopathies[ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyNerve Degenerationalpha-SynucleinDementiapathologyNeurology (clinical)businessNeuroscience030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFrontotemporal dementiadementiaRevue neurologique
researchProduct